Given the association of the newer-generation TKIs with cardiovascular diseases (especially in patients with pre-existing risk factors) [37,38,208] and the prognostic impact of comorbidities on CML survival, a better definition of the role of CHIP mutations in CML is worthy of further exploration for an improved management of the lifelong TKI algorithm. The gene discussed is STUB1; the disease is cardiovascular disorder.